National Cancer Institute (NCI): Leukemia trials

The registry lists 271 Leukemia studies with National Cancer Institute (NCI) as lead sponsor. 5 are open to participants now and 89 have results posted.

Early Phase 1 1Phase 1 152Phase 2 120Phase 3 8No phase 20(a study in two phases counts in both)

Studies

Page 1 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancersNot yet recruitingNCT07524530Phase 2
• Natural History Study of Early Life Exposures in Agriculture (ELEA)Enrolling by invitationNCT07328516
• Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell TransplantRecruitingNCT06856226
• Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell TherapyRecruitingNCT05237986
• Leukapheresis for CAR or Adoptive Cell Therapy ManufacturingEnrolling by invitationNCT03226704
• Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid LeukemiaCompletedNCT04277442Phase 1Results posted
• Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary SyndromeCompletedNCT04185220Phase 1Results posted
• T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin LymphomaTerminatedNCT04160195Phase 1Results posted
• Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT03813147Phase 1Results posted
• Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte LeukemiaTerminatedNCT03759184Phase 1Results posted
• Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene RearrangementTerminatedNCT03724084Phase 1/2Results posted
• Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 RearrangementCompletedNCT03701295Phase 1/2Results posted
• Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their CaregiversCompletedNCT03538587Not applicableResults posted
• CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesCompletedNCT03448393Phase 1Results posted
• Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT03092674Phase 2/3Results posted
• Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene RearrangementCompletedNCT02828358Phase 2Results posted
• Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)CompletedNCT02689453Phase 1Results posted
• Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/LymphomaCompletedNCT02631746Phase 2Results posted
• Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic LeukemiaCompletedNCT02484430Phase 2Results posted
• Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell TransplantationCompletedNCT02356159Phase 1/2Results posted
• Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaTerminatedNCT02129062Phase 2Results posted
• Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid LeukemiaTerminatedNCT01907815Phase 2Results posted
• Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT01870596Phase 2Results posted
• Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT01802333Phase 3Results posted
• Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01789255Phase 2Results posted
• Ruxolitinib for Adult T-Cell LeukemiaTerminatedNCT01712659Phase 1/2Results posted
• Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or LymphomaCompletedNCT01593696Phase 1Results posted
• Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic LeukemiaCompletedNCT01515176Phase 1/2Results posted
• Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LeukemiaCompletedNCT01445080Phase 1/2Results posted
• Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT01420926Phase 2Results posted
• Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaTerminatedNCT01383447Phase 1/2Results posted
• Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01369849Phase 1/2Results posted
• Tipifarnib in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT01361464Phase 2Results posted
• Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01349972Phase 2Results posted
• Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow TransplantationCompletedNCT01338987Phase 2Results posted
• Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT01326728Results posted
• Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsCompletedNCT01326702Phase 1/2Results posted
• A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and LeukemiasCompletedNCT01287104Phase 1Results posted
• Study of Akt Inhibitor MK2206 in Patients With Relapsed LymphomaCompletedNCT01258998Phase 2Results posted
• Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT01256398Phase 2Results posted
• AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01253447Phase 2Results posted
• Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT01253070Phase 2Results posted
• Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01238211Phase 2Results posted
• Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid LeukemiaCompletedNCT01168219Phase 2Results posted
• Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell LeukemiaCompletedNCT00924170Phase 1/2Results posted
• Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell LeukemiaTerminatedNCT00924040Phase 2Results posted
• Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the BloodCompletedNCT00923910Phase 1/2Results posted
• Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell LeukemiaActive, not recruitingNCT00923013Phase 2Results posted
• Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AMLCompletedNCT00895934Phase 1/2Results posted
• Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedNCT00873093Phase 2Results posted
• Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00795002Phase 2Results posted
• Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00742625Phase 1/2Results posted
• Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00720109Phase 2/3Results posted
• Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid LeukemiaCompletedNCT00666588Phase 2Results posted
• Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00634244Phase 2Results posted
• Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid LeukemiaCompletedNCT00602771Phase 2Results posted
• Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic LeukemiaCompletedNCT00602459Phase 2Results posted
• Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid LeukemiaCompletedNCT00588809Phase 2Results posted
• Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic LeukemiaCompletedNCT00563290Phase 2Results posted
• Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune SystemCompletedNCT00520130Phase 1/2Results posted
• Aflibercept in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00509249Phase 2Results posted
• Decitabine in Treating Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00492401Phase 2Results posted
• Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT00475150Phase 2Results posted
• MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic LeukemiaCompletedNCT00462605Phase 2Results posted
• Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaCompletedNCT00451048Phase 2Results posted
• Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00416598Phase 2Results posted
• Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00407966Phase 2Results posted
• Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00398112Phase 2Results posted
• Sunitinib in Treating Patients With Idiopathic MyelofibrosisTerminatedNCT00387426Phase 2Results posted
• 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00381550Phase 2Results posted
• Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte LeukemiaTerminatedNCT00363779Phase 2Results posted
• PXD101 in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00357032Phase 2Results posted
• Lenalidomide in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00352365Phase 2Results posted
• LMB-2 to Treat Hairy Cell LeukemiaCompletedNCT00321555Phase 2Results posted
• Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid LeukemiaCompletedNCT00313586Phase 2Results posted
• Vorinostat in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00305773Phase 2Results posted
• Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaTerminatedNCT00303966Phase 2Results posted
• Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT00290810Phase 2Results posted
• CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00290472Phase 2Results posted
• Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin LymphomaTerminatedNCT00288067Phase 1/2Results posted
• Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaTerminatedNCT00262925Phase 2Results posted
• Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell LeukemiaTerminatedNCT00117845Phase 2Results posted
• Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT00098670Phase 2Results posted
• Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic LeukemiaTerminatedNCT00098371Phase 2Results posted
• Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid LeukemiaCompletedNCT00096122Phase 1/2Results posted
• MDX-010 in Treating Patients With Recurrent or Refractory LymphomaTerminatedNCT00089076Phase 1/2Results posted
• Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic LeukemiaCompletedNCT00077922Phase 2Results posted
• Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph CancersTerminatedNCT00074490Phase 2Results posted
• Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic LeukemiaCompletedNCT00061945Phase 1/2Results posted
• Campath-1H for Treating Adult T-Cell Leukemia/LymphomaCompletedNCT00061048Phase 2Results posted
• Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic LymphomaCompletedNCT00058240Phase 1/2Results posted
• Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00039377Phase 2Results posted
• Anti-Tac for Treatment of LeukemiaCompletedNCT00001941Phase 1/2Results posted
• Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression AnalysisCompletedNCT00001586Phase 2Results posted
• Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)WithdrawnNCT06210750Phase 2
• Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT03745352Phase 2
• Optimal Methods of Disease Detection in Children and Young Adults With Acute Lymphoblastic Leukemia in the Pediatric Oncology BranchCompletedNCT03627208
• Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT02791919Phase 1
• Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative DisordersCompletedNCT02210858Phase 1/2
• Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionTerminatedNCT02109224Phase 1